Spironolactone Plus Metformin in Polycystic Ovary Syndrome
The investigators examined whether a combined therapy with low-dose spironolactone plus metformin is more effective than metformin alone in 52 overweight/obese Polycystic Ovary Syndrome (PCOS) patients.
Polycystic Ovary Syndrome
DRUG: Metformin|DRUG: Metformin plus Spironolactone
Metformin versus Metformin plus low-dose Spironolactone on metabolic parameters of Patients with Polycystic Ovary Syndrome: a randomized study, We evaluated metabolic parameters across anthropometric parameters: height, weight, waist circumference, BMI, glycemia, lipid profile, blood count, coagulation parameters, hepatic and renal function indexes, OGTT and HOMA-IR. The diagnosis of MetS was established according to the ATPIII criteria, six months
Spironolactone versus Metformin plus spironolactone in hyperandrogenism in Polycystic Ovary Syndrome, We evaluated hyperandrogenism across Hirsutism Score, measuring total testosterone, SHBG, Î”4androstenedione, DHEA-S and FAI. All patients underwent ovarian ultrasound examination., six months
In the present prospective, randomized study, we evaluated the efficacy of a combined therapy with metformin and low-dose spironolactone as compared to metformin alone on the clinical and endocrine-metabolic alterations of PCOS patients.